Can hunger return while semaglutide still changes food intake?

Hunger and food intake answer different questions

A change in how hungry you feel can be unsettling when you expected the feeling to remain constant. Before interpreting it, separate three questions: what you feel, what you eat, and what your clinician is monitoring. One cannot be substituted for the other two.

The 2026 study discussed here was published online in June, not this week. Its useful contribution is the longer observation period and the separation of subjective appetite from measured lunch intake. It is background for a conversation about expectations, rather than a home test of medication effectiveness. [1]

A practical reading habit is to underline the outcome in a headline. Does the paper measure hunger ratings, food consumed at a test meal, body weight or nutrient intake? Rewrite the headline with that exact outcome before applying it to your own experience.

What the 60-week trial found

Tronieri and colleagues randomized 120 adults with overweight or obesity, without diabetes, to injectable semaglutide 2.4 mg or placebo; both groups received lifestyle counselling. Researchers repeatedly recorded appetite and measured how much participants ate at a laboratory lunch after a standard breakfast. [1]

The semaglutide group had larger reductions from baseline in lunch energy intake than placebo at weeks 20, 40 and 60. Appetite-rating differences favoured semaglutide at week 20 but were not statistically significant at weeks 40 or 60. This does not prove identical appetite or an absent treatment effect. [1]

The trial had differential dropout, assessed a laboratory meal rather than everyday intake, and had a predominantly female and White sample. Novo Nordisk partly funded it; the authors reported that the company had no role in the study. These qualifications belong beside the finding. [1]

Why earlier percentages describe different measurements

A 2017 crossover study involved 30 adults with obesity, with 12 weeks in each treatment period and semaglutide increased to 1.0 mg. Compared with placebo, energy consumed across the freely chosen lunch, evening meal and snacks on the test day was 24% lower after a standard breakfast. The breakfast itself was not part of that freely chosen intake. This was a small, short mechanistic experiment. [2]

A separate 2021 parallel-group study randomized 72 adults with obesity for 20 weeks, using semaglutide increased to 2.4 mg or placebo. The often-quoted 35% lower intake concerned the laboratory lunch at week 20, not a measured reduction across every day of treatment. Both earlier studies were funded by Novo Nordisk. [2] [3]

Those percentages are not a scale of how strongly a person should feel the medicine. Different participants, treatment periods and meal measurements prevent a direct ranking. None gives you a daily calorie reduction to copy, or a reason to adjust medication.

Use two columns when your own experience changes

Write the first column as an observation: for example, I noticed hunger before lunch again this week. Keep it separate from an interpretation such as the treatment has stopped working. The observation is information you can report; the interpretation asks a medical question that the observation alone cannot settle.

Use the second column for the question you want answered: what else should we review alongside this change? Add relevant context you already know, such as a changed routine or difficulty completing meals, without deciding that it explains the change. You do not need to create a complete scientific experiment at home.

Consider a hypothetical appointment note: I feel hungrier before lunch than I did earlier in treatment. I would like to review this alongside the measures and nutrition advice we already agreed. This example opens a discussion. It neither demonstrates a medication problem nor tells you to ignore one.

If you also want to describe eating, use the existing food-log guide and mark estimates honestly. A home record remains a description of your circumstances, not the controlled laboratory endpoint used in these trials.

Ask what would change a decision

A useful appointment question connects an observation to the next decision. Ask which information your clinician needs, how it should be recorded, and when to review it. Bring your existing plan so the discussion starts with your circumstances rather than an internet average.

You might ask: what are we monitoring besides appetite? Which changes should prompt earlier contact? If eating has become difficult, who can review my nutrition plan? The answers should come from your own care team. A research explainer cannot determine an appropriate dose, whether to continue a medicine or your personal food intake.

The distinction also protects against an overly reassuring headline. A group result can explain why two measures need not move together; it cannot confirm that any individual symptom is expected or harmless. Seek medical advice about a concerning change rather than using the paper to dismiss it.

Keep a compact evidence card

When you encounter another appetite claim, copy four prompts: who was studied; what was measured; what was compared; and when it was measured. Then add the question the study leaves unanswered. If a headline says daily intake but the methods say one lunch, preserve that boundary in your notes.

This is an original Peptis reading aid, not a validated clinical instrument. Its purpose is to help you keep a result at its measured scope and bring a clearer question to your existing care team.

For broader routine planning, the free Peptis continuity check produces a written summary of strength, protein and maintenance priorities and opens a starter training plan. It can help you organise those priorities; it does not assess whether a medicine is working or offer clinical treatment.

Does feeling hungry mean semaglutide has stopped working?

The study cannot decide that for an individual. Appetite ratings and laboratory intake are different outcomes; discuss a change alongside your existing care plan.

Should I aim to eat 24% or 35% less because of these studies?

No. Those comparisons describe different controlled meal measurements in study groups. They are not personal daily intake targets.

Can these results guide a dose change?

No. Medication decisions belong with your prescribing clinician. The evidence card is a way to prepare questions, not a dosing tool.